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Abstract
Introduction—Previous studies have tested the hypothesis that calpain and/or proteasome
inhibition is beneficial in Duchenne Muscular Dystrophy, based largely on evidence that calpain
and proteasome activities are enhanced in the mdx mouse.
Methods—mRNA expression of ubiquitin proteasome and calpain system components were
determined using RT-PCR in skeletal muscle and heart in the golden retriever muscular dystrophy
model. Similarly, calpain 1/2 and proteasome activities were determined using fluorometric
activity assays.
Results—We found that less than half of the muscles tested had increases in proteasome activity,
and only one-half had increased calpain activity. Additionally, transcriptional regulation of the
ubiquitin proteasome system was most pronounced in the heart, where numerous components
were significantly decreased.
Discussion—This study illustrates the diversity of expression and activities of the ubiquitin
proteasome and calpain systems, which may lead to unexpected consequences in response to
pharmacologic inhibition.
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Introduction
The muscle damage sustained in Duchenne Muscular Dystrophy (DMD) is cleared by two
major proteolytic systems: the calpain and ubiquitin proteasome systems 1, 2.The
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involvement of these proteolytic systems has prompted investigators to explore their role in
the pathogenesis of DMD mainly using the mdx mouse model 2–14. At least 8 studies have
tested the hypothesis that calpain and/or proteasome inhibition is beneficial in disease, and
most have shown significant improvement in histology and function in short term studies
(summarized in Supplemental Table 1 and Supplemental Table 2)3–7, 10, 12, 13. Paralleling
the therapeutic utility of calpain and proteasome inhibition on the mdx phenotype, there has
been the largely uniform evidence that calpain and proteasome activities are enhanced in
DMD (Supplemental Table 1 and Supplemental Table 2).
These studies have been limited by their sampling of only 1 or 2 skeletal muscle types (+/
−diaphragm) and their use of the mdx mouse model, which has a relatively mild phenotype
compared to DMD in humans. We hypothesized that different muscle groups, including the
heart, might have a more diverse expression and activity of calpain and the ubiquitin
proteasome systems. If this is true, it might result in unexpected and possibly unintended
consequences in response to calpain and proteasome inhibition. In this study, we
investigated the diversity of proteasome and calpain activities in five representative skeletal
muscles and the heart in the golden retriever muscular dystrophy (GRMD) model at six
months of age. Despite the more severe disease phenotype in these animals, we found that
only 1 (of 6) muscles had increased trypsin-like (proteasome) activity. In all 6 muscles
tested, including the left ventricle, no differences in caspase-like and chymotrypsin-like
(proteasome) activities were seen. Similarly, none of the 5 skeletal muscles or the left
ventricle had significant increases in calpain 1&2 activities. Additionaly, transcriptional
regulation of the ubiquitin proteasome system was most pronounced in the heart, where
numerous components were significantly decreased, including the ubiquitin ligase CHIP,
MDM2, and the E2 enzyme UNC4/5. The left ventricle also had decreased calpain 1 and
calpain 2 expression, without affecting overall calpain 1 & 2 activities. These findings
illustrate the muscle-specific differences in calpain and ubiquitin proteasome system
expression and activity in GRMD, a DMD model that parallels human disease in many
ways 15–18. These findings illustrate how proteasome and calpain inhibitors used to treat
DMD might have unexpected consequences that are muscle specific, particularly in the
heart.
Materials and Methods
Animals
Dogs were cared for and utilized according to principles outlined in the National Institutes
of Health Guide for the Care and Use of Laboratory Animals. Newborn GRMD dogs were
identified based on elevation of serum creatine kinase (CK). Genotype was confirmed by
PCR when CK results were ambiguous. Dogs subsequently developed characteristic clinical
signs. Long digital extensor, lateral head of gastrocnemius, vastus lateralis, biceps femoris,
cranial sartorius, and left ventricle of the heart were harvested from 7 GRMD and 8 control
dogs at 6 months of age (Supplemental Table 3). Dogs were anesthetized using conventional
preanesthetic drugs, propofol (normal dogs only), and sevoflurane. Of the 15 dogs, 12 were
harvested after being euthanized, and 3 underwent biopsies before recovery and subsequent
adoption (see Supplemental Table 3). The muscle(s) were exposed sharply at surgery to
allow removal of a sample of approximately 1 × 0.5 × 0.5 cm, snap frozen in liquid nitrogen,
and stored at −80°C for further processing. These studies have been approved by the
University of North Carolnia Institutional Animal Care and Use Committee.
Real time PCR analysis of UPS components
Total RNA was isolated, cDNA was generated, and PCR products were amplified as
described previously 19. TaqMan probes were from Applied Biosystems, Inc. (Carlsbad,
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CA) and included dog specific probes for calpain 1 (Cf02704115_m1), calpain 2
(Cf02645870_m1), CHIP (Cf02644017_m1), MAFbx (Cf02667148_mi), MDM2
(Cf026759237_m1), MuRF1 (Cf02649993_mi), PSMA6 (Cf02666165_g1), PSMB4
(Cf01123846_m1), PSME1 (Cf02646187_g1), ubiquitin (Mm01622233_g1), UBC9
(Cf02655738_g1), UNC4/5 (Cf02657121_m1). Relative mRNA expression was normalized
to 18S (Hs99999901_s1).
Measuring 26S proteasome activity using fluorogenic substrates
Assaying specific 26S proteasome activities was performed as previously described 20–22.
Briefly, tissue was homogenized in lysis buffer(250 mM sucrose, 50 mM Tris, pH 7.5, 5
mM MgCl2, 0.5 mM EDTA, 1 mM dithiothreitol, 2mM ATP, and 0.025% Digitonin).
Approximately 25 micrograms of protein was added to the proteasome reaction buffer (50
mM Tris, pH 7.5, 40 mM KCl, 1 mM MgCl2, 1 mM dithiothreitol, 0.5 mM ATP, and 0.05
mg/ml bovine serum albumin) that contained fluorogenic substrates (75µM of Suc-LLVY-
AMC for Chymotrypsin-like activiy; 150µM of Boc-LRR-AMC for Trypsin-like activiy;
75µM of Ac-nLPnLD-AMC for Caspase-like activity) (Enzo Life Sciences International,
Inc., Farmingdale, NY). Fluorescence was measured with a Wallace Victor 2
spectrophotometer (excitation 355 nm, emission 460 nm) 40 times every 2 minutes at 37°C.
Parallel samples were preincubated with the proteasome inhibitor epoxomycin (20 µM) for
30 min at 37°C to determine the non-specific substrate hydrolysis. These fluorescence units
were then subtracted from each measurement.
Measuring Calpain1/2 activity using fluorogenic substrates
Calpain 1/2 activity assays were performed using the Sensolyte® AMC Calpain Activity
Flurometric Assay Kit according to the manufacturer’s protocol (Anaspec, Inc, Fremont,
CA). Briefly, calpain 1/2 activity in tissue extracts was assessed by hydrolysis of the
fluorogenic peptide substrate succinyl-leucine-leucine-valine-tyrosine-4-methyl-7-
courmarylamide (Suc-LLVY-AMC). Fifty µg per well of tissue extracts were put into a 96-
well black opaque plate followed by the addition of the substrate solution. Fluorescence was
measured using a GENios microplate reader (excitation 355 nm, emission 442 nm)(Tecan
Group Ltd., Durham, NC).
Summaries of previous studies of muscular dystrophy, proteasome, and calpains
Summaries of previous studies are summarized in supplemental tables 1 & 2. The studies
were identified by searching PubMed using the search criteria indicated in the tables.
Statistical Analysis
A Rank-Sum test was performed, because most of the data were determined to be non-
parametric using a normality test and (when appropriate) an equal variance test in Sigma
Stat 2.03 (Systat Software, Inc, San Jose, CA). Statistical significance was set at P≤0.05.
Results
Differential expression of the ubiquitin proteasome components is muscle specific
The ubiquitin ligases MuRF1 and MAFbx/atrogin-1 have been prominently studied in
skeletal muscle atrophy and are linked mechanistically to degradation of the sarcomere 23.
Their role in cardiac hypertrophy, atrophy, and metabolism has also recently been
reported 19, 24–26. Therefore, we investigated their expression in the GRMD model. MuRF1
and MAFbx/atrogin-1 mRNA levels in GRMD did not differ from age-matched controls in
all the muscles investigated (Figure 1A and 1B). The five GRMD skeletal muscles (long
digital extensor, lateral head of gastrocnemius, vastus lateralis, biceps femoris, and cranial
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sartorius) generally had increased MuRF1 and MaFBx expression compared to controls, but
these increases were not uniform.
Apoptosis has also been linked to the pathophysiology of DMD 27–29. The ubiquitin ligases
carboxyl terminus of Hsp70 interacting protein (CHIP) and murine double minute 2
(MDM2) have been reported to inhibit apoptosis by targeting p53 for degradation by the
proteasome 30–33. Furthermore, CHIP has been implicated in the pathogenesis of a
Caenorhabditis elegans form of muscular dystrophy 34. We therefore measured CHIP and
MDM2 expression in GRMD. Both CHIP and MDM2 were signficantly decreased in the left
ventricle (Figure 1C and 1D); MDM2 was increased only in the vastus lateralis (Figure 1D).
Expression of CHIP and MDM2 did not significantly differ from control animals in the long
digital extensor, lateral head of the gastrocnemius, bicep femoris, and cranial sartorius
(Figure 1C and 1D). However, individual animals had increased CHIP and MDM2 in the
biceps femoris and cranial sartorius. The expression of ubiquitin ligases in GRMD was
largely unaffected in the skeletal muscles, while the downregulation of 2 of the 4
investigated in this study were seen in the heart, as summarized in Table 1.
To determine if expression of other UPS components are altered in GRMD, we measured
mRNA expression levels of ubiquitin, uncoordinated phenotype 4/5 (UNC4/5), a protein
chaperone involved in integrating myosin into the sarcomere 35, and ubiquitin-like protein
SUMO-1 conjugating enzyme 9 (UBC9), the sole conjugating (E2) enzyme for small
ubiquitin-like modifer protein (SUMO) 36. There were no differences in mRNA expression
levels of ubiquitin between GRMD and control muscles (Figure 2A), consistent with a
previous study in DMD patients8. UNC4/5 expression was decreased in GRMD left
ventricle compared to controls, but it was unaffected in the five skeletal muscles (Figure
2B). UBC9 expression was significantly increased only in the cranial sartorius compared to
controls (Figure 2C).
Expression of proteasome subunits is significantly decreased in the GRMD heart
We next determined the expression of 3 different proteasome subunits: PSMA6, PSMB4,
and PSME1 (Figure 3). PSMA6 and PSMB4 are noncatalytic subunits of the 20S
proteasome, 37 and PSME1 is the alpha subunit in the activator heteroheptamer ring which
binds to one or both ends of the 20S proteasome and allows peptides to enter the 20S
subunit 37. GRMD left ventricle had a significant decrease in the expression of all three
proteasome subunits (Figure 3A–3C). PSMB4 was increased in 4 of the 5 GMRD skeletal
muscles (Figure 3B). Expression of PSMA6 and PSME1 was unchanged in all GRMD
skeletal muscles.
Proteasome activity is generally unchanged in GRMD skeletal muscle and heart
Using a fluorimetric assay, we assayed proteasome trypsin-like, caspase-like, and
chymotrypsin-like activities from GRMD and control animals (Figure 4). The only
significantly different proteasome activity in GRMD muscles was found in the lateral head
of the gastrocnemius, with increased trypsin-like activity. Individual animals had increases
in caspase-like and chymotrypsin-like activity in the gastrocnemius as well, but these
increases were not uniform. Similarly, all three activities were increased in the long-digital
extensor, but this was not uniform throughout the animals (i.e. not signficant). The
disconnect between the decreased proteasome expression shown in Figure 3 and the
unaffected proteasome activities is pronounced in the GRMD left ventricle (summarized in
Table 2).
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Calpain 1 and calpain 2 expression is decreased in the GRMD heart
Calpains are Ca2+-dependent cysteine proteases which initiate the release of proteins from
the myofibril, making myofibrillar proteins available for degradation by the UPS 38. Calpain
1 (µ-calpain) and calpain 2 (m-calpain), so named because they are activated by micromolar
and millimolar Ca2+ concentrations, respectively, are the most widely studied members of
the calpain family and have been shown to be involved in the pathogenesis of
DMD 3, 8, 9, 14, 39. Since we found that the UPS is altered in GRMD muscle, we next
measured calpain 1 and 2 expression in GRMD. Both calpain 1 and 2 expression were
significantly decreased in the GRMD left ventricle (Figure 5A & 5B). Calpain 2 expression
was increased in many of the animals in all 5 GRMD skeletal muscles, although only 3
muscle groups reach signficance (gastrocnemius, vastus lateralis, and cranial sartorius)
(Figure 5B).
Calpain 1&2 Activity is not uniformly increased in GRMD skeletal muscles and heart
Calpain1&2 activity was not significantly different from age-matched controls in any of the
skeletal muscles or left ventricle (Figure 5C). However, 4 of the 5 skeletal muscles and the
left ventricle had individuals with increased calpain 1 & 2 activity, which did not reach
significance.
Discussion
For nearly 2 decades, the role of intracellular proteolysis has been appreciated in DMD 1. At
least 8 studies have reported that calpain and/or proteasome inhibition is beneficial in
disease (summarized in blue-Supplemental Table 1 and Supplemental Table 2)3–7, 10, 12, 13.
Paralleling the therapeutic utility of calpain and proteasome inhibition on the mdx mouse
phenotype, there has been largely uniform evidence in 4 studies that calpain and proteasome
activities are enhanced in DMD (summarized in white-Supplemental Table 1 and
Supplemental Table 2). What is striking about these studies is that they largely investigated
short term proteasome and calpain inhibtion on mainly the milder mdx muscular dystrophy
in a very limited number of skeletal muscles, generally 3 or less. In this study, we
investigated more broadly how muscular dystrophy in the GRMD model affected
components of the ubiquitin proteasome system, the proteasome, and calpain activities
(summarized in Tables 1 & 2 and the supplemental results section). While we detected
increased proteasome and calpain activities in a minority of the muscles tested, we found
that the heart had dramatically decreased expression of ubiquitin ligases (CHIP, MDM2),
the proteasome (PSMA6, PSMB4, PSME1), and calpains (calpain 1 and calpain 2). This
raises the concern that proteasome inhibition may inhibit proteasome and calpain activities
in muscles that do not have increased proteolysis, and may potentially further inhibit
muscles that have decreased expression of ubiquitin proteasome components and calpains,
particularly the heart.
Inhibiting proteasome and calpain activities in muscles without increased activity is
worrisome considering their diverse roles in the maintenance of the cell. This is a point that
may have become obscured by the large number of studies that implicate these proteolytic
systems in the degradation of specific substrate targets in the sarcomere40, 41. The activity of
the proteasome has been implicated at multiple points in the regulation of gene expression42.
The 26S proteasome specifically plays a role in modifying activators, co-activators, and co-
repressors of transcription necessary for gene transcription. Proteasome activity is also
essential in numerous signaling pathways, including calcineurin, β-catenin, NF-κB, and
caspases, which are responsible for the regulation of cell death 43. Similar to the proteasome,
the calpain system plays diverse roles in cell biology. For example, calpains have been
implicated in proliferation, differentiation, cell cycle progression, apoptosis, and cell
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signaling 44. Calpain activity has been implicated in signal transduction through PKC,
GSK-3β, CaMK II and IV, myosin light chain kinase, and calcineurin (recently reviewed by
Bukowska, et al. 44). Calpains have also been implicated in the regulation of transcription
factor regulation, including NF-κB, AP-1 (c-Jun/c-Fos), and c-Myc among others 44. Given
the diverse roles both the proteasome and calpains play in cell biology, inhibiting their
activity broadly throughout all cells could potentially uncover many side-effects, at the very
least, and potentially worsen outcomes.
Example of potential side effects come from experimental studies of proteasome inhibitors.
Proteasome inhibitors are useful for the treatment of multiple myeloma, because they
enhance cell death in myeloma cells 45. How the heart may be affected by these therapies is
just now starting to be appreciated. For example, inhibiting the proteasome in
cardiomyocytes can induce cell death in cultured cardiomyocytes 46, 47 and can adversely
affect cardiac function in hearts challenged by pressure-overload48, 49. In humans treated
with proteasome inhibitors for multiple myeloma, ischemic heart disease complications have
been reported 50, raising the concern of systemic proteasome inhibition. The activity of
calpains in cardiomyocytes has also been implicated in cardiac pathology44. While
inhibiting calpains experimentally has been shown to reduce myocardial stunning,
contractile dysfunction due to tachypacing, and damage due to atrial fibrillation, long term
therapeutic benefits have not been studied44. For example, while calpain inhibition may
inhibit apoptosis in some cardiac conditions, it is not clear if this is protective or induces
alternative forms of cell death, namely necrosis 51. Lastly, the complexity of interpreting all
these studies is that DMD patients largely have an underlying cardiac defect caused by
DMD itself. Specifically, most DMD patients exhibit dilated cardiomyopathy and
ventricular arrhythmias due to their disease 52–58, thus the heart has increased to further
insult. This should raise concerns for unexpected side effects from inhibiting proteasome or
calpain activity in a more complex milleu of DMD-related cardiac disease and should raise
concern for testing these therapies in DMD patients.
Limiting factors in this study are the number of animals that were included and the
variability seen in the GRMD disease model. While statistical differences were seen in 19 of
the parameters tested, an additional 19 parameters had trends that were close, but not
statistically different (summarized in Tables 1 & 2). The trends that did not reach statistical
significance were likely due to the fact that this study utilized a limited number of highly
variable samples. This variation makes it more difficult to delineate differences because of
the heterogeneity of the population being studied. Despite these weaknesses, the major
conclusions of this manuscript are largely not affected by these issues and allow us to show
that both calpain and the ubiquitin proteasome systems are differentially regulated by
different muscle types and are largely not increased.
Although we have emphasized the expanding role of the ubiquitin proteasome and calpain
systems in diverse biological processes, they are best known for their roles in protein quality
control in muscle 40, 41. Since widespread destruction of muscle and the sarcomere are
involved in the pathophysiology of muscular dystrophy, inhibiting the destruction of
damaged proteins may be one reason that proteasome and calpain inhibition have worked.
By slowing the destruction of damaged sarcomere, more sarcomere is kept and used, despite
its quality not being perfect. The buildup of post-translational modifications and reduced
quality control could be the compromise needed to maintain function. However, the concern
is not so much for the few skeletal muscles improved with proteasome and/or calpain
inhibition. It is more for the heart, which in DMD patients is compromised to begin with and
insulted further by inhibition of 2 of the 3 proteolytic systems necessary for maintenance of
the cardiomyocytes.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Ubiquitin ligase (E3) expression in golden retriever muscular dystrophy (GRMD)
Quantitative mRNA expression analysis of the ubiquitin ligases (A) Muscle Ring Finger-1
(MuRF1), (B) Muscle F-box protein (MAFbx), (C) carboxyl terminus of Hsp70-interacting
protein (CHIP), and (D) Mouse double minute-2 (MDM2) in GRMD lateral digital extensor,
the lateral head of the gastrocnemius, vastus lateralis, biceps femoris, left ventricle, and
cranial sartorius. mRNA expression is shown as the fold change compared to age-matched
control animals. Data represent 3–5 dogs per group (outlined in Supplemental Table 3), as
indicated above each vertical box plot. The vertical box plot presents the median (50%
percentile), indicated by the middle line inside the box, the 75% percentile indicated by the
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top of the box, and the 25% percentile indicated by the bottom of the box. A Rank-Sum test
was used to determine the differences in mRNA expression. *p≤0.05.
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Figure 2. Expression of ubiquitin, UNC4/5, and the E2 ubiquitin conjugating enzyme UBC9 in
GRMD skeletal muscle and heart
Quantitative mRNA expression analysis of (A) ubiquitin, (B) the protein chaperone
UNC4/5, and (C) E2 UBC9 in the GRMD lateral digital extensor, the lateral head of the
gastrocnemius, vastus lateralis, biceps femoris, left ventricle, and cranial sartorius. mRNA
expression is shown as the fold change compared to age-matched control animals. Data
represent 3–5 dogs per group (outlined in Supplemental Table 3), as indicated above each
vertical box plot. The vertical box plot presents the median (50% percentile), indicated by
the middle line inside the box, the 75% percentile indicated by the top of the box, and the
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25% percentile indicated by the bottom of the box. A Rank-Sum test was used to determine
the differences in mRNA expression. *p≤0.05.
Wadosky et al. Page 14
Muscle Nerve. Author manuscript; available in PMC 2012 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3. Proteasome subunit expression in GRMD skeletal muscle and heart
Quantitative mRNA expression analysis of the proteasome subunits (A) PSMA6, (B)
PSMB4, and (C) PSME1 in GRMD long digital extensor, lateral head of the gastrocnemius,
vastus lateralis, biceps femoris, left ventricle, and cranial sartorius. mRNA expression is
shown as the fold change compared to age-matched control animals. Data represent 3–5
dogs per group (outlined in Supplemental Table 3), as indicated above each vertical box
plot. The vertical box plot presents the median (50% percentile), indicated by the middle
line inside the box, the 75% percentile indicated by the top of the box, and the 25%
percentile indicated by the bottom of the box. A Rank-Sum test was used to determine the
differences in mRNA expression. *p≤0.05.
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Figure 4. Muscle specific proteasome activities in GRMD
(A) Trypsin-like, (B) caspase-like, and (C) chymotrypsin-like activities in GRMD long
digital extensor, lateral head of the gastrocnemius, vastus lateralis, biceps femoris, left
ventricle, and cranial sartorius. Proteasome activities are presented as arbitrary fluorscent
units (AFU). Data represent 3–5 dogs per group (outlined in Supplemental Table 3), as
indicated above each vertical box plot. The vertical box plot presents the median (50%
percentile), indicated by the middle line inside the box, the 75% percentile indicated by the
top of the box, and the 25% percentile indicated by the bottom of the box. A Rank-Sum test
was used to determine the differences in proteasome activity. *p≤0.05.
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Figure 5. Muscle specific calpain1/2 activities in GRMD
Quantitative mRNA expression analysis of (A) calpain 1, and (B) calpain 2 in GRMD long
digital extensor, lateral head of the gastrocnemius, vastus lateralis, biceps femoris, left
ventricle, and cranial sartorius. Expression levels are presented as a percentage of age-
matched controls. (C) Calpain1/2 activity determined by a fluorimetric based-assay on
GRMD long digital extensor, lateral head of the gastrocnemius, vastus lateralis, biceps
femoris, left ventricle, and cranial sartorius. mRNA expression is shown as the fold change
compared to age-matched control animals. Calpain1/2 activity is presented as the relative
fluorometric units. Data represent 3–5 dogs per group (outlined in Supplemental Table 3), as
indicated above each vertical box plot. The vertical box plot presents the median (50%
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percentile), indicated by the middle line inside the box, the 75% percentile indicated by the
top of the box, and the 25% percentile indicated by the bottom of the box. A Rank-Sum test
was used to determine the differences in mRNA expression and calpain 1/2 activity.
*p≤0.05.
Wadosky et al. Page 18
Muscle Nerve. Author manuscript; available in PMC 2012 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Wadosky et al. Page 19
Ta
bl
e 
1
Su
m
m
ar
y 
of
 th
e 
ub
iq
ui
tin
 p
ro
te
as
om
e 
sy
st
em
 e
xp
re
ss
io
n 
in
 G
R
M
D
 sk
el
et
al
 m
us
cl
e 
an
d 
he
ar
t c
om
pa
re
d 
to
 a
ge
 m
at
ch
ed
 c
on
tr
ol
s
“I
nc
” 
de
no
te
s t
ha
t t
he
 m
R
N
A
 e
xp
re
ss
io
n 
or
 p
ro
te
as
e 
ac
tiv
ity
 w
as
 si
gn
ifi
ca
nt
ly
 In
cr
ea
se
d 
fo
r t
he
 in
di
ca
te
d 
G
R
M
D
 m
us
cl
e 
co
m
pa
re
d 
to
 w
ild
ty
pe
. “
–
“ 
de
no
te
s t
ha
t t
he
 p
ro
te
as
e 
ac
tiv
ity
 w
as
 u
nc
ha
ng
ed
 fo
r t
he
 in
di
ca
te
d 
G
R
M
D
 m
us
cl
e 
co
m
pa
re
d 
to
 w
ild
ty
pe
. “
D
ec
” 
in
di
ca
te
s t
he
 e
xp
re
ss
io
n 
w
as
 D
ec
re
as
ed
in
 G
R
M
D
 sa
m
pl
es
 c
om
pa
re
d 
to
 c
on
tro
ls
. P
 v
al
ue
s g
iv
en
 fo
r r
el
at
io
ns
hi
ps
 tr
en
di
ng
 (<
0.
2)
; t
he
 d
ire
ct
io
n 
of
 th
e 
tre
nd
 is
 g
iv
en
 in
 p
ar
en
th
es
es
.
M
us
cl
e
M
uR
F1
E
xp
re
ss
io
n
M
A
FB
x/
A
tr
og
in
-1
E
xp
re
ss
io
n
C
H
IP
E
xp
re
ss
io
n
M
D
M
2
E
xp
re
ss
io
n
U
bi
qu
iti
n
E
xp
re
ss
io
n
U
N
C
4/
5
E
xp
re
ss
io
n
U
B
C
9
E
xp
re
ss
io
n
Lo
ng
 d
ig
ita
l e
xt
en
so
r
-
-
-
p=
0.
14
 (I
nc
)
-
-
p=
0.
07
 (I
nc
)
La
te
ra
l h
ea
d 
ga
st
ro
cn
em
iu
s
-
-
-
-
-
p=
0.
11
 (D
ec
)
p=
0.
19
 (I
nc
)
V
as
tu
s l
at
er
al
is
-
-
-
In
c
-
-
p=
0.
07
 (I
nc
)
B
ic
ep
 fe
m
or
is
-
-
-
p=
0.
10
 (I
nc
)
-
-
p=
0.
10
 (I
nc
)
Le
ft 
ve
nt
ric
le
-
-
D
ec
D
ec
-
D
ec
-
C
ra
ni
al
 sa
rto
riu
s
-
-
-
p=
0.
14
 (I
nc
)
-
-
In
c
Muscle Nerve. Author manuscript; available in PMC 2012 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Wadosky et al. Page 20
Ta
bl
e 
2
Su
m
m
ar
y 
of
 th
e 
pr
ot
ea
so
m
e 
an
d 
ca
lp
ai
n 
ex
pr
es
si
on
 a
nd
 a
ct
iv
iti
es
 in
 G
R
M
D
 sk
el
et
al
 m
us
cl
e 
an
d 
he
ar
t c
om
pa
re
d 
to
 a
ge
 m
at
ch
ed
 c
on
tr
ol
s
Th
e 
am
ou
nt
 o
f a
tro
ph
y/
hy
pe
rtr
op
hy
 d
at
a 
w
as
 a
da
pt
ed
 fr
om
 K
or
ne
ga
y,
 e
t a
l. 
59
. “
In
c”
 d
en
ot
es
 th
at
 th
e 
m
R
N
A
 e
xp
re
ss
io
n 
or
 p
ro
te
as
e 
ac
tiv
ity
 w
as
si
gn
ifi
ca
nt
ly
 In
cr
ea
se
d 
fo
r t
he
 in
di
ca
te
d 
G
R
M
D
 m
us
cl
e 
co
m
pa
re
d 
to
 w
ild
ty
pe
. “
–“
 d
en
ot
es
 th
at
 th
e 
pr
ot
ea
se
 a
ct
iv
ity
 w
as
 u
nc
ha
ng
ed
 fo
r t
he
 in
di
ca
te
d
G
R
M
D
 m
us
cl
e 
co
m
pa
re
d 
to
 w
ild
ty
pe
. “
D
ec
” 
in
di
ca
te
s t
he
 e
xp
re
ss
io
n 
w
as
 D
ec
re
as
ed
 in
 G
R
M
D
 sa
m
pl
es
 c
om
pa
re
d 
to
 c
on
tro
ls
. N
D
 d
en
ot
es
 th
at
 th
e
at
ro
ph
y/
hy
pe
rtr
op
hy
 d
at
a 
w
as
 n
ot
 p
re
vi
ou
sl
y 
de
te
rm
in
ed
. P
 v
al
ue
s g
iv
en
 fo
r r
el
at
io
ns
hi
ps
 tr
en
di
ng
 (<
0.
2)
; t
he
 d
ire
ct
io
n 
of
 th
e 
tre
nd
 is
 g
iv
en
 in
pa
re
nt
he
se
s.
M
us
cl
e
PS
M
A
6
E
xp
re
s
si
on
PS
M
B
4
E
xp
r
es
si
o
n
PS
M
E
1
E
xp
re
s
si
on
Pr
ot
ea
so
m
e 
A
ct
iv
ity
T
ry
ps
in
-li
ke
 (l
ef
t)
C
as
pa
se
-li
ke
 (m
id
dl
e)
C
hy
m
ot
ry
ps
in
-li
ke
 (r
ig
ht
)
C
al
pa
in
 1
E
xp
re
ss
io
n
C
al
pa
in
 2
E
xp
re
ss
io
n
C
al
pa
in
1/
2
A
ct
iv
ity
A
tr
op
hy
/H
y
pe
rt
ro
ph
y
U
se
Lo
ng
 d
ig
ita
l e
xt
en
so
r
-
In
c
p=
0.
14
 (D
ec
)
p=
0.
05
7 
(I
nc
)
p=
0.
05
7 
(I
nc
)
p=
0.
05
7 
(I
nc
)
-
p=
0.
07
 (I
nc
)
p=
0.
05
7 
(I
nc
)
Se
ve
re
 A
tro
ph
y
Ex
te
ns
io
n 
of
 d
ig
its
La
te
ra
l h
ea
d 
ga
st
ro
cn
em
iu
s
-
In
c
-
In
c
-
-
-
In
c
-
A
tro
ph
y
Ex
te
ns
io
n 
of
 h
oc
k
V
as
tu
s l
at
er
al
is
-
In
c
-
p=
0.
05
7 
(I
nc
)
-
-
p=
0.
07
 (I
nc
)
In
c
-
N
D
Ex
te
ns
io
n 
of
 st
ifl
e
B
ic
ep
 fe
m
or
is
-
p=
0.
10
 (I
nc
)
-
-
-
-
-
-
-
A
tro
ph
y
Ex
te
ns
io
n 
of
 st
ifl
e 
an
d 
hi
p
Le
ft 
ve
nt
ric
le
D
ec
D
ec
D
ec
-
-
-
D
ec
D
ec
p=
0.
05
7 
(I
nc
)
N
D
Sy
st
em
ic
 B
lo
od
 C
irc
ul
at
io
n
C
ra
ni
al
 sa
rto
riu
s
P=
0.
14
 (I
nc
)
In
c
-
-
-
-
p=
0.
14
 (I
nc
)
In
c
p=
0.
05
7 
(I
nc
)
H
yp
er
tro
ph
y
Fl
ex
io
n 
of
 h
ip
Muscle Nerve. Author manuscript; av ilable in PMC 2012 October 1.
